Treating Patients With IV Iron Therapy: Special Considerations

ANNA CE Satellite Symposium - Las Vegas, Nevada, April 21, 2005
Welcome, Introduction, and Program Overview
Moderator: Steven Fishbane, MD
Assessing the Validity of Higher Serum Ferritin Values in Determining Iron Status
Steven Fishbane, MD

Anemia Management in Pediatric Patients on Chronic Dialysis
Bradley A. Warady, MD

Questions and Answers
Speakers and moderators

Steven Fishbane, MD
Associate Director, Nephrology
Associate Chairman, Department of Medicine
Winthrop-University Hospital
Mineola, New York

Bradley A. Warady, MD
Chief, Section of Pediatric Nephrology
Director, Dialysis and Transplantation
The Children’s Mercy Hospital
Kansas City, Missouri

This satellite symposium is sponsored by an unrestricted educational grant from Watson Pharma, Inc. This activity has been planned and produced in accordance with CE guidelines and policies. From a CE symposium held on April 21, 2005 at the American Nephrology Nurses' Association (ANNA) Annual Meeting in Las Vegas, Nevada. This symposium was approved by ANNA. It was not part of the official ANNA Annual Meeting.
This activity has been awarded 2.1 contact hours by the American Nephrology Nurses Association (ANNA) which is accredited as a provider and approver of continuing education in nursing by the American Nurses Credentialing Center-Commission on Accreditation (ANCC-COA).
Posting Date: August 12, 2005
CE Credit Eligible Through: May 1, 2007
CE Credit Hours/Completion Time: 2.1
Target Audiences: Nurses, nurse practitioners, and other healthcare professionals who treat and manage patients with CKD.
Method of participation: Listen to the talk, read the PubMed abstracts linked to data slides and talk references, take the post-test, read the linked abstracts in the post-test answer feedback material.
After participating in this program, the participant should be able to:
  1. Define serum ferritin and the current understanding of it in terms of safety and efficacy
  2. Review K/DOQI recommendations for treating patients based on serum ferritin levels
  3. Describe special concerns that exist in treating anemia in pediatric patients on dialysis
  4. Discuss dosing guidelines for administering IV iron in pediatric patients
  5. Evaluate the safety and efficacy of IV iron therapy
See individual talks.

This ANNA Satellite symposium was developed in conjunction with Fallon Medica, and the ANNA, and sponsored by a restricted educational grant from Watson Pharma, Inc.

The CE policy and disclosure statements of the American Nephrology Nurses' Association are given in detail on the Symposium Home Page. The CE policy statements of HDCN are listed on this page.